darunavir sandoz 800 mg apvalkotās tabletes
sandoz d.d., slovenia - darunavīrs - apvalkotā tablete - 800 mg
darunavir sandoz 400 mg apvalkotās tabletes
sandoz d.d., slovenia - darunavīrs - apvalkotā tablete - 400 mg
darunavir sandoz 600 mg apvalkotās tabletes
sandoz d.d., slovenia - darunavīrs - apvalkotā tablete - 600 mg
fluconazole unifarma 50 mg cietās kapsulas
unifarma, sia, latvia - flukonazols - kapsula, cietā - 50 mg
digoxicor 0,5 mg/2 ml šķīdums injekcijām/infūzijām
sopharma ad, bulgaria - digoksīns - Šķīdums injekcijām/infūzijām - 0,5 mg/2 ml
esmocard lyo 2500 mg pulveris infūziju šķīduma koncentrāta pagatavošanai
orpha-devel handels und vertriebs gmbh, austria - esmolola hidrohlorīds - pulveris infūziju šķīduma koncentrāta pagatavošanai - 2500 mg
fluconazole baxter 2 mg/ml šķīdums infūzijām
baxter holding b.v., netherlands - flukonazols - Šķīdums infūzijām - 2 mg/ml
mycomax 150 mg cietās kapsulas
zentiva, k.s., czech republic - flukonazols - kapsula, cietā - 150 mg
diflucan 2 mg/ml šķīdums infūzijām
pfizer limited, united kingdom - flukonazols - Šķīdums infūzijām - 2 mg/ml
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiski līdzekļi - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.